SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+10.43%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$260M
AUM Growth
+$260M
(+21%)
Cap. Flow
+$28.4M
Cap. Flow
% of AUM
10.91%
Top 10 Holdings %
Top 10 Hldgs %
28.77%
Holding
78
New
17
Increased
25
Reduced
14
Closed
14
Top Buys
| 1 |
Eli Lilly
LLY
|
$6.83M |
| 2 |
Merck
MRK
|
$6.45M |
| 3 |
AstraZeneca
AZN
|
$5.27M |
| 4 |
Cencora
COR
|
$4.9M |
| 5 |
Cigna
CI
|
$4.25M |
Top Sells
| 1 |
AbbVie
ABBV
|
$7.1M |
| 2 |
Universal Health Services
UHS
|
$6.51M |
| 3 |
Cardinal Health
CAH
|
$5.01M |
| 4 |
Smith & Nephew
SNN
|
$3.82M |
| 5 |
UnitedHealth
UNH
|
$3.54M |
Sector Composition
| 1 | Healthcare | 93.84% |
| 2 | Energy | 1.15% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Boston Scientific
BSX
$156B
| $8.5M | 3.27% | 260,000 +85,000 | +49% | +$2.78M |
|
2
Stryker
SYK
$150B
| $8.44M | 3.25% | 50,000 +15,000 | +43% | +$2.53M |
|
|
WCG
3
DELISTED
Wellcare Health Plans, Inc.
WCG
| $7.53M | 2.9% | 30,586 +8,619 | +39% | +$2.12M |
|
4
Bristol-Myers Squibb
BMY
$96B
| $7.47M | 2.87% | 135,000 +55,000 | +69% | +$3.04M |
|
5
Humana
HUM
$36.5B
| $7.44M | 2.86% | 25,000 -5,000 | -17% | -$1.49M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $7.41M | 2.85% | 43,600 +8,600 | +25% | +$1.46M |
|
7
Molina Healthcare
MOH
$9.8B
| $7.35M | 2.82% | 75,000 -5,000 | -6% | -$490K |
|
8
Teva Pharmaceuticals
TEVA
$21.1B
| $6.93M | 2.67% | 285,000 -70,000 | -20% | -$1.7M |
|
9
Centene
CNC
$14.3B
| $6.91M | 2.66% | 56,100 -8,024 | -13% | -$989K |
|
|
10
Eli Lilly
LLY
$657B
| $6.83M | 2.62% | +80,000 | New | +$6.83M |
|
|
11
Cencora
COR
$56.5B
| $6.82M | 2.62% | 80,000 +57,500 | +256% | +$4.9M |
|
12
Biogen
BIIB
$19.4B
| $6.53M | 2.51% | 22,500 +7,500 | +50% | +$2.18M |
|
|
13
Merck
MRK
$210B
| $6.45M | 2.48% | +106,237 | New | +$6.45M |
|
14
Thermo Fisher Scientific
TMO
$186B
| $6.21M | 2.39% | 30,000 +10,000 | +50% | +$2.07M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.12M | 2.35% | 65,000 +45,000 | +225% | +$4.24M |
|
16
Intuitive Surgical
ISRG
$170B
| $5.98M | 2.3% | 12,500 | – | – |
|
17
Elevance Health
ELV
$71.8B
| $5.95M | 2.29% | 25,000 +5,000 | +25% | +$1.19M |
|
18
Baxter International
BAX
$12.7B
| $5.91M | 2.27% | 80,000 -20,000 | -20% | -$1.48M |
|
19
Abbott
ABT
$231B
| $5.79M | 2.23% | 95,000 -40,000 | -30% | -$2.44M |
|
20
Viatris
VTRS
$12.3B
| $5.78M | 2.22% | 160,000 | – | – |
|
21
Incyte
INCY
$16.5B
| $5.7M | 2.19% | 85,000 +40,000 | +89% | +$2.68M |
|
|
22
AstraZeneca
AZN
$248B
| $5.27M | 2.03% | +150,000 | New | +$5.27M |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.05M | 1.94% | 17,500 +2,500 | +17% | +$721K |
|
|
24
UnitedHealth
UNH
$281B
| $5.05M | 1.94% | 20,573 -14,427 | -41% | -$3.54M |
|
25
Zoetis
ZTS
$69.3B
| $4.69M | 1.8% | 55,000 +15,000 | +38% | +$1.28M |
|